# Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy

> **NCT00754845** · PHASE3 · COMPLETED · sponsor: **Canadian Cancer Trials Group** · enrollment: 1918 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** letrozole
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00754845
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11-23
- **Primary completion:** 2015-12-21
- **Final completion:** 2017-04-19
- **Target enrollment:** 1918 (ACTUAL)
- **Last updated:** 2023-08-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00754845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00754845, "Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00754845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*